Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of AtriCure, Inc. (NASDAQ:ATRC)

Key Points

• Rep. Gil Cisneros disclosed a purchase of AtriCure (NASDAQ:ATRC) stock valued at $1,001–$15,000 on March 3 in his "150 MAIN STREET TRUST > BANK OF AMERICA" account (filing disclosed April 7).
• AtriCure shares traded around $28.12 and the company recently beat quarterly EPS estimates with 13.1% revenue growth, but remains unprofitable (negative margins) with analysts holding a consensus "Moderate Buy" and an average target of $48.43.
• Separately, Cisneros reported multiple other trades (including a $15,001–$50,000 purchase of Fabrinet on March 27), and AtriCure insider Vinayak Doraiswamy sold 5,000 shares on March 12 at about $29.83.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of AtriCure, Inc. (NASDAQ:ATRC). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in AtriCure stock on March 3rd. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of MACOM Technology Solutions NASDAQ: MTSI on 3/27/2026.
• Purchased $1,001 - $15,000 in shares of StandardAero NYSE: SARO on 3/27/2026.
• Purchased $1,001 - $15,000 in shares of FirstService NASDAQ: FSV on 3/27/2026.
• Sold $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 3/27/2026.
• Sold $1,001 - $15,000 in shares of Advanced Energy Industries NASDAQ: AEIS on 3/27/2026.
• Sold $1,001 - $15,000 in shares of Flex NASDAQ: FLEX on 3/27/2026.
• Purchased $1,001 - $15,000 in shares of LPL Financial NASDAQ: LPLA on 3/27/2026.
• Purchased $1,001 - $15,000 in shares of DoorDash NASDAQ: DASH on 3/27/2026.
• Sold $1,001 - $15,000 in shares of Viavi Solutions NASDAQ: VIAV on 3/27/2026.
• Purchased $15,001 - $50,000 in shares of Fabrinet NYSE: FN on 3/27/2026.

AtriCure Stock Performance

ATRC stock traded down $0.10 during trading on Thursday, hitting $28.12. 232,353 shares of the company traded hands, compared to its average volume of 654,485. The stock's 50-day simple moving average is $31.54 and its 200 day simple moving average is $35.24. AtriCure, Inc. has a 1 year low of $27.26 and a 1 year high of $43.18. The company has a market cap of $1.40 billion, a PE ratio of -117.33 and a beta of 1.43. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.96 and a quick ratio of 2.99.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings results on Tuesday, February 17th. The medical device company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.10. The company had revenue of $140.50 million for the quarter, compared to analyst estimates of $140.50 million. AtriCure had a negative net margin of 2.14% and a negative return on equity of 1.15%. The firm's revenue was up 13.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.33) earnings per share. On average, equities analysts expect that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

Institutional Trading of AtriCure

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC boosted its holdings in AtriCure by 64.7% in the 2nd quarter. Squarepoint Ops LLC now owns 186,965 shares of the medical device company's stock valued at $6,127,000 after purchasing an additional 73,468 shares in the last quarter. Riverwater Partners LLC increased its holdings in AtriCure by 79.2% during the 3rd quarter. Riverwater Partners LLC now owns 60,322 shares of the medical device company's stock valued at $2,126,000 after acquiring an additional 26,657 shares in the last quarter. Citigroup Inc. raised its position in shares of AtriCure by 182.0% during the 3rd quarter. Citigroup Inc. now owns 57,085 shares of the medical device company's stock worth $2,012,000 after purchasing an additional 36,839 shares during the last quarter. Hood River Capital Management LLC increased its position in AtriCure by 2.1% during the 2nd quarter. Hood River Capital Management LLC now owns 3,061,059 shares of the medical device company's stock worth $100,311,000 after purchasing an additional 61,852 shares in the last quarter. Finally, Kennedy Capital Management LLC boosted its stake in shares of AtriCure by 36.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 836,916 shares of the medical device company's stock worth $29,501,000 after purchasing an additional 222,529 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company's stock.

Insider Buying and Selling at AtriCure

In other news, insider Vinayak Doraiswamy sold 5,000 shares of the business's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $29.83, for a total transaction of $149,150.00. Following the completion of the sale, the insider directly owned 96,875 shares of the company's stock, valued at $2,889,781.25. The trade was a 4.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ATRC. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of AtriCure in a report on Wednesday, January 21st. Zacks Research lowered shares of AtriCure from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 18th. Needham & Company LLC reiterated a "buy" rating and set a $45.00 price target on shares of AtriCure in a report on Thursday, February 12th. JPMorgan Chase & Co. cut shares of AtriCure from an "overweight" rating to a "neutral" rating and set a $36.00 price objective for the company. in a research report on Wednesday, February 11th. Finally, UBS Group lowered their price objective on shares of AtriCure from $60.00 to $55.00 and set a "buy" rating for the company in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $48.43.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.